Anti-Human CD279 (PD-1) (Nivolumab) - Dylight® 488

PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.

0.2 mg/ml

DyLight® 488

This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Human PD-1

Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.

5133

PD-1